Fox Chase clinical trial tests first of its kind antibody

Patients with HER2-positive cancers can have dramatic responses to HER2-targeted drugs but eventually develop resistance to the agents. With that problem in mind, Fox Chase Cancer Centre researchers are testing a novel type of antibody called MM-111 in patients with HER2-positive disease who have progressed on standard therapy...

Read the whole article on

More from